Cilcare CIL001 tinnitus program (company-reported development)
Record details
- Authors: Cilcare (company communications)
- Journal / source: Company announcements / trade press (2025)
- Design: Drug development program: intratympanic candidate targeting cochlear synaptopathy; Phase 1b/2a program advancing to Phase 2a in chronic tinnitus (US and Europe)
- Sample: —
- Primary endpoint: —
- Randomized: No · Sham/placebo-controlled: No · Independent of the manufacturer: No
What this research found
COMPANY-REPORTED ONLY: single intratympanic injection targeting cochlear synaptopathy; the company describes a Phase 2a in chronic tinnitus (2025–26); €40M Series A closed Dec 2024. No peer-reviewed efficacy data exist — every efficacy statement is unverified.
Tracked as pipeline intelligence, not evidence. Registry check (ClinicalTrials.gov, 19 October 2026): paliroden (CIL001) NCT07826507 is Phase 1/2, not yet recruiting (estimated start January 2027); adverse events are the primary outcome and speech-in-noise is among the secondary outcomes; no tinnitus measure was found among the registered outcomes.
Limitations and conflicts of interest
No peer-reviewed data.
Funding / conflicts: Company-reported.
Primary sources
Used as evidence for
This is an original summary from the Tinnitus Evidence verified database, checked against the primary source — not a reproduction of the publisher's abstract.